The Use of Pulmonary Hyperinflation With the Mechanical Ventilator in Cardiac Patients
Launched by INSTITUTO DE CARDIOLOGIA DO RIO GRANDE DO SUL · Oct 5, 2020
Trial Information
Current as of May 23, 2025
Unknown status
Keywords
ClinConnect Summary
Mechanical ventilation (MV) is used to reduce work and reverse or prevent fatigue of the respiratory muscles, decrease oxygen consumption and maintain gas exchange. In addition to the benefits given to patients undergoing MV, there is a high risk of accumulating bronchial secretions, related to pathology and / or therapeutic intervention. Pulmonary hyperinflation is widespread in patients in intensive care centers (ICUs) as a bronchial hygiene therapy, being used in 40% of 64 Australian ICUs as demonstrated by Dennis et al., Through contact with physical therapists. Mechanical hyperinflatio...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Interned in the Post-Operative Unit (UPO), Intensive Care Center (ICU) and Emergency.
- • Using invasive mechanical ventilation for more than 48 hours.
- • Hemodynamically stable (MAP 60-120 mmHg).
- Exclusion Criteria:
- • Diagnosis of ventilator-associated pneumonia.
- • Individuals with pneumothorax and undrained hemothorax.
- • Subcutaneous emphysema.
- • Patients with peak pressure\> 40 cmH2O.
- • Patients diagnosed with neurological disease within 72 hours.
About Instituto De Cardiologia Do Rio Grande Do Sul
The Instituto de Cardiologia do Rio Grande do Sul is a leading research and clinical institution dedicated to advancing cardiovascular health through innovative clinical trials and comprehensive patient care. Located in Brazil, the institute specializes in cardiology and is committed to enhancing the understanding and treatment of cardiovascular diseases. With a team of experienced healthcare professionals and researchers, the Instituto de Cardiologia do Rio Grande do Sul focuses on developing cutting-edge therapies and improving clinical outcomes, while fostering collaboration with national and international partners in the field of cardiovascular research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Porto Alegre, Rio Grande Do Sul, Brazil
Patients applied
Trial Officials
Bruna Eibel, Dr
Principal Investigator
Instituto de Cardiologia
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials